TY - JOUR
T1 - Postoperative Major Adverse Cardiac Events in Patients With Systemic Lupus Erythematosus
AU - Bruera, Sebastian
AU - Lei, Xiudong
AU - Blau, Brandon
AU - Zhao, Hui
AU - Deswal, Anita
AU - Yazdany, Jinoos
AU - Giordano, Sharon H.
AU - Suarez-Almazor, Maria E.
N1 - Funding Information:
Supported in part by the National Cancer Institute (NCI) P30 CA016672 and by the Duncan Family Institute. Dr. Yazdany is supported by NIH grants K24-AR-074534 and P30-AR-070155. Dr. Giordano is supported by the Cancer Prevention and Research Institute of Texas (CPRIT) grant RP160674 and Komen SAC150061.
Publisher Copyright:
© 2022 The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.
PY - 2022/6
Y1 - 2022/6
N2 - Objectives: Patients with systemic lupus erythematosus (SLE) have a high risk of cardiovascular disease that could potentially increase postoperative major adverse cardiac events (MACE). We determined the rate of MACE in patients with SLE undergoing noncardiac surgery using national claims-based data. Methods: This was a retrospective cohort study using Optum Clinformatics Data Mart from 2007 to 2020. We identified a cohort of patients with SLE who had undergone noncardiac surgeries using Current Procedural Terminology codes. We also identified two control cohorts without SLE, one with diabetes mellitus (DM) and one without DM. After matching cases and controls by age and sex, the odds of MACE were estimated using multivariable logistic regression models also including race and the Revised Cardiac Risk Index (RCRI) scores. We also examined use of preoperative cardiac testing. Results: We identified 4750 patients with SLE, 496,381 DM controls, and 1,484,986 non-DM controls. After matching, the odds ratio (OR) for MACE in patients with SLE versus non-DM controls was 1.51 (95% confidence interval 1.09-2.08), which decreased after adjustment for RCRI score (OR: 0.97, 95% confidence interval 0.7-1.36). No significant differences were observed in the incidence of MACE between patients with SLE and DM controls (0.82 vs 1.04, P = 0.16). High-risk patients with SLE (RCRI score of ≥3) were less likely to receive preoperative cardiac testing than non-DM controls (42.7% vs 35.1%, P < 0.05). Conclusion: Patients with SLE have an increased risk of postoperative MACE, which is driven by increased RCRI scores. Concerningly, high-risk patients received less cardiac testing 2 months before surgery than non-DM controls.
AB - Objectives: Patients with systemic lupus erythematosus (SLE) have a high risk of cardiovascular disease that could potentially increase postoperative major adverse cardiac events (MACE). We determined the rate of MACE in patients with SLE undergoing noncardiac surgery using national claims-based data. Methods: This was a retrospective cohort study using Optum Clinformatics Data Mart from 2007 to 2020. We identified a cohort of patients with SLE who had undergone noncardiac surgeries using Current Procedural Terminology codes. We also identified two control cohorts without SLE, one with diabetes mellitus (DM) and one without DM. After matching cases and controls by age and sex, the odds of MACE were estimated using multivariable logistic regression models also including race and the Revised Cardiac Risk Index (RCRI) scores. We also examined use of preoperative cardiac testing. Results: We identified 4750 patients with SLE, 496,381 DM controls, and 1,484,986 non-DM controls. After matching, the odds ratio (OR) for MACE in patients with SLE versus non-DM controls was 1.51 (95% confidence interval 1.09-2.08), which decreased after adjustment for RCRI score (OR: 0.97, 95% confidence interval 0.7-1.36). No significant differences were observed in the incidence of MACE between patients with SLE and DM controls (0.82 vs 1.04, P = 0.16). High-risk patients with SLE (RCRI score of ≥3) were less likely to receive preoperative cardiac testing than non-DM controls (42.7% vs 35.1%, P < 0.05). Conclusion: Patients with SLE have an increased risk of postoperative MACE, which is driven by increased RCRI scores. Concerningly, high-risk patients received less cardiac testing 2 months before surgery than non-DM controls.
UR - http://www.scopus.com/inward/record.url?scp=85133363291&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85133363291&partnerID=8YFLogxK
U2 - 10.1002/acr2.11424
DO - 10.1002/acr2.11424
M3 - Article
C2 - 35294107
AN - SCOPUS:85133363291
SN - 2578-5745
VL - 4
SP - 511
EP - 519
JO - ACR Open Rheumatology
JF - ACR Open Rheumatology
IS - 6
ER -